3 Reasons Trump Victory Brings New Day for Biotech

BEN LEVISOHN | November 10, 2016

article image
Tax reform and cash access may increase M&A: A major platform issue for the Trump campaign was corporate tax reform. Trump has suggested he would lower the corporate tax to 15% and provide a one-time repatriation holiday with a 10% tax rate. For Biotech, this positions Amgen and Gilead to gain access to ~$60B in cash and could significantly lower Biogen's tax rate (Biogen is the only large-cap Biotech with a tax rate not in the teens or lower) and increase EPS by ~10%. Given that many BioPharma companies are looking for inorganic growth to drive new top-line growth, the increased access to cash could potentially drive a new wave of pipeline acquisitions.

Spotlight

Bharat Serums and Vaccines Limited

Bharat Serums And Vaccines Limited is one of the fastest growing bio pharmaceutical companies in India. BSV established in 1971 by the late Dr. Vinod Daftary researches, develops, manufactures, and markets injectable biological, pharmaceutical, and biotechnology products. BSV's products portfolio includes plasma derivatives, monoclonals, fertility hormones, antifungals, anaesthetics, cardiovascular drugs, and equine immunoglobulin /antitoxins. The R&D of drug delivery systems, biotechnology/recombinant therapeutics, and biological/equine products; In addition, BSV offers products in the areas of gynaecology, assisted reproductive technology, critical care, emergency medicine, neurology, nephrology, haematology, and urology.

OTHER ARTICLES

Ruminating on Bioprocessing 4.0

Article | February 18, 2020

The Bioprocessing 4.0 concept seeks to apply automation and technology to the digital transformation of biologics manufacturing. As the paradigm moves forward, it faces barriers to its adoption, according to Eric Langer, president of BioPlan Associates. “Perhaps the greatest challenges involve unsecured links and adapting the applications to areas where automation is critically needed today,” says Langer. “Unresolved security issues could seriously affect a company’s data in a regulated environment, so they will need to have iron-clad anti-hacking protection in place. Unfortunately, cyber security is not yet a top focus for the industry.”

Read More

Cell Out? Lysate-Based Expression an Option for Personalized Meds

Article | February 18, 2020

Cell-free expression (CFE) is the practice of making a protein without using a living cell. In contrast with cell line-based methods, production is achieved using a fluid containing biological components extracted from a cell, i.e., a lysate. CFE offers potential advantages for biopharma according to Philip Probert, PhD, a senior scientist at the Centre for Process Innovation in the U.K.

Read More

2 Small-Cap Biotech Stocks You Haven't Heard of, But Should Know About

Article | April 17, 2020

With everything that's going on with the COVID-19 pandemic, many healthcare companies have grabbed plenty of spotlight during these challenging times. At the same time, a number of otherwise promising businesses have slipped under the radar. That's especially true for small-cap biotech stocks that aren't actively involved in developing tests, vaccines or treatments for COVID-19. Vaccine developers, protective equipment producers, and healthcare service providers are all attracting plenty of attention during this pandemic, but there are just as many promising biotech stocks that aren't involved in these areas. Here are two such companies that you might have missed, but they deserve a spot on your watch list.

Read More

Top 10 biotech IPOs in 2019

Article | February 24, 2020

The big question at the start of 2019 was whether the IPO window would stay open for biotech companies, particularly those seeking to pull off ever-larger IPOs at increasingly earlier stages of development. The short answer is yes—kind of. Here’s the long answer: In the words of Renaissance Capital, the IPO market had “a mostly good year.” The total number of deals fell to 159 from 192 the year before, but technology and healthcare companies were standout performers. The latter—which include biotech, medtech and diagnostics companies—led the pack, making up 43% of all IPOs in 2019. By Renaissance’s count, seven companies went public at valuations exceeding $1 billion, up from five the year before

Read More

Spotlight

Bharat Serums and Vaccines Limited

Bharat Serums And Vaccines Limited is one of the fastest growing bio pharmaceutical companies in India. BSV established in 1971 by the late Dr. Vinod Daftary researches, develops, manufactures, and markets injectable biological, pharmaceutical, and biotechnology products. BSV's products portfolio includes plasma derivatives, monoclonals, fertility hormones, antifungals, anaesthetics, cardiovascular drugs, and equine immunoglobulin /antitoxins. The R&D of drug delivery systems, biotechnology/recombinant therapeutics, and biological/equine products; In addition, BSV offers products in the areas of gynaecology, assisted reproductive technology, critical care, emergency medicine, neurology, nephrology, haematology, and urology.

Events